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Calcium and Vitamin D Intake in Women 
Most women are unaware of the protective benefits of an adequate diet 
against postmenopausal calcium loss. This article is directed towards im-
proving the reader’s knowledge about the role of dietary factors in improv-
ing bone strength. 
Adequate calcium intake has been shown to reduce bone loss and to pre-
vent fractures in women nearing menopause (peri-menopausal) and post-
menopausal women.  Some women may be at greater risk than others 
because of smoking, alcohol consumption, sedentary lifestyle, usage of 
certain medication (heparin, steroids), having had a fracture previously 
and menopause etc.  
Calcium requirement rises at menopause, or whenever estrogen is lost 
because calcium absorption efficiency and renal conservation are both 
estrogen dependent. For most postmenopausal women, the target cal-
cium intake is 1200 mg/day. Calcium strongly enhances the bone-
protective effects of hormonal therapy in postmenopausal women, and 
sufficient calcium intake is an essential part of any treatment regimen for 
patients with established osteoporosis.  
 
Benefits of Calcium and Vitamin D: 
Women having been prescribed medication e.g. hormones, bisphospho-
nates, calcitonin, etc need an adequate amount of calcium for maximum 
benefit. 
Calcium has also been associated with beneficial effects in several non-
skeletal disorders, primarily hypertension, colorectal cancer, obesity, and 
nephrolithiasis. Although the extent of those effects has not been fully elu-
cidated. In the presence of adequate vitamin D status, adequate calcium 
intake has been shown to reduce bone loss in peri-menopausal and postmenopausal women and to 
reduce fractures in postmenopausal women older than 60 years with low calcium intakes. 
 
Requirements: 
The recommended calcium requirement is 1000 mg daily for pre-menopausal women aged 25 to 50 
years, and varies from 1200 to 1500 mg daily for postmenopausal women. Recommended vitamin D 
intake to achieve a serum 25(OH)D of 30 ng/ml or more is usually achieved with a daily intake of at 
least 400 IU (for women aged 51 - 70 years) to 600 IU (for women > 70 years). In the absence of 
sunlight, daily intakes of 800 to 1000 IU are recommended since wearing sunscreen with a sun pro-
tection factor of 8 or above has been shown to reduce vitamin D production by 95%. 
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Sources:  
Undoubtedly the best source of calcium is dairy products.  
Approximately 3 cups of dairy products daily provide the 1200-mg  
calcium target. Women at increased risk for inadequate dietary calcium  
intake include those who are lactose intolerant, follow a pure vegetarian  
diet (vegan), or have poor eating habits. 
Sources of vitamin D include sunlight exposure, vitamin D fortified 
foods (e.g., milk, some yogurts, orange juices, some breads, oily fish,  
such as salmon or mackerel), and vitamin supplements. 
 
Adverse effects: 
Calcium doses higher than 2150 mg daily have been shown to increase  
renal calculi by 17%, and women with a history of renal calculi should  
not exceed the age-appropriate dosage and should increase intake of  
water with calcium. 
The safe upper limit of vitamin D daily is 2000 IU. Higher doses may  
cause vitamin D intoxication and increased risk for hypercalciuria and  
hypercalcemia. Doses higher than 10,000 IU daily should be avoided. 
 
Key message:   
• Inadequate calcium intake in women is associated with bone loss. 
• Women at higher risk for poor intake include peri-menopausal and postmenopausal women, ve-
gans, and those who are lactose intolerant, and those who have poor eating habits. 
• There are no reported cases of calcium intoxication from food sources, and cases associated with 
supplements are rare. 
• Laboratory tests for serum vitamin D include 25(OH)D, which can help identify women who are vi-
tamin D deficient and therefore likely to be calcium deficient even when consuming adequate 
amounts of calcium from diet and supplements. 
• Approximately 3 cups of dairy products daily provide the 1200-mg target. If calcium supplementa-
tion is needed, each dose must not exceed the age-appropriate allowance and should be con-
sumed with a large glass of water. 
 
Conclusion:  
Postmenopausal health has taken a back seat to most heath care issues in Pakistan. This is com-
pounded by ambivalence, both on the administrative and personal level, and most women in our soci-
ety women tend to ignore symptoms and signs until too late.   Simple awareness of issues may lead 
to alleviation of a number of health problems.  
 
Contributed by: Dr Rozilla Sadia Khan, Senior Instructor, Department of Obstetrics/Gynaecology—AKUH 
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FDA Safety Alert, February 2007—Rosiglitazone (Avandia) 
Glaxo SmithKline (GSK) notified health care professionals of the results of a randomised, double-blind parallel group 
study [ADOPT] of 4,360 patients with recently diagnosed type 2 diabetes mellitus followed for 4-6 years to compare 
glycemic control with rosiglitazone relative to metformin and glyburide monotherapies. Significantly more female pa-
tients who received rosiglitazone experienced fractures of the upper arm, hand, or foot, than did female patients who 
received either metformin or glyburide. At GSK's request, an independent safety committee reviewed an interim analy-
sis of fractures in another large; ongoing; controlled clinical trial and preliminary analysis was reported as being con-
sistent with the observations from ADOPT. Health care professionals should consider the risk of fracture when initiat-
ing or treating female patients with type 2 diabetes mellitus with rosiglitazone.  
ADR Reducing Tip 
 
1. Fast infusion of IV     
Ciprofloxacin can induce 
rashes, injection site 
pain,  erythema, and 
even thrombophlebitis. 
2. The extent and           
frequency of this ADR 
can be lessened if      
infused through           
anticubital vein rather 
than through small, more 
peripheral veins 
3. IV Ciprofloxacin should 
not be infused over less 
than 60 minutes 
Remember!  
ADR reporting is crucial 
for patient safety 
 Volume 14, Issue 1 Page 3 
Management of Intractable Hiccups 
 
Intractable hiccups, defined as hiccups lasting more than a month, are a rare condition that occur primarily in 
male individuals with a history of one or more organic diseases or psychological disorders. A hiccup is a re-
peated involuntary spasmodic contraction of the diaphragm followed by a sudden closure of the glottis which 
checks the inflow of air and produces the characteristic sounds. Hiccups result when afferent or efferent 
nerves to the muscles of respiration, or the medullary centers controlling these muscles are irritated.  
 
Causes: 
 
• The underlying pathophysiology of intractable hiccups remains to be elu-
cidated, but is believed to involve organic, drug-induced, and/or psycho-
logical causes.  
• Drugs reported to cause intractable hiccups have included antibiotics, 
antipsychotics and perphenazine, corticosteroids, etoposide, and 
megestrol acetate.  
• Other non-drug related proposed causes include light anesthesia                                                   
when muscle relaxation is produced by neuromuscular blocking agents, 
gastric distension, and diaphragmatic irritation. If left untreated, intracta-
ble hiccups may result in severe discomfort, decreased physical strength, 
mental depression, and possibly death.  
 
Treatment:   
 
Removal of Offending Agents:  
Patients suffering from intractable hiccups believed to be drug- induced should be given a drug holiday, if 
practical; chemically- induced hiccups often spontaneously resolve upon drug discontinuation 
Non-Pharmacological Treatment:  
A plethora of non-pharmacological treatments for hiccups exist, including: holding your breath; slowly drinking 
a glass of water; pressure on eyeballs; swallowing; irritation of nasal mucosa to produce sneezing; mustard 
plaster, ice bag, ethyl chloride spray, or ether applied to the epigastrium; pressure over carotid sinus between 
thumb and forefinger for one minute, grasping the artery at the midpoint of the anterior border of the sterno-
cleidomastoid; strong digital pressure over the phrenic nerves in their course behind the sternoclavicular 
points; forceable traction of the tongue; induction of nausea or vomiting by tickling the throat; gasping with 
sudden fright, the Valsalva maneuver, hyperventilation, and drinking water from the 'wrong side' of a glass. 
Pharmacological Treatment: 
When non-pharmacological treatments failed, various drug therapies have been proposed. The only drug ap-
proved by the FDA for the treatment of intractable hiccups is chlorpromazine. Several case reports and re-
views of cases have described good to excellent results as follows: 
 
 
 
 
 
 
 
 
 
 
 
Contributed by: Syed Yasir Ali, Pharmacist, Department of Pharmacy Services—AKUH 
Metoclopramide 5 to 10 mg 
given IM or IV  
Chlorpromazine 25 to 50 mg 
IV with a repeat dose 2 to 4 
hours later IM or IV 
Amitriptyline up to 30 mg/day 
in divided doses 
Haloperidol 2 mg IM  Baclofen 10 mg orally 3 times 
daily  
Nifedipine 10 to 20 mg orally 
3 times daily  
Oral Valproic acid titrated to 
plasma levels ranging from 34 
to 96 mcg/ml 
Atropine sulfate 0.4 mg 3 to 4 times per day followed by heavy 
sedation with pentobarbital 200 to 400 mg  
 
 
QUIZ 
Do you know besides        
Multiple Myeloma,  what 
else is a FDA approved    
indication for Thalidomide ? 
 
See answer on pager # 4 
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Facts About Therapeutic Drug Monitoring  
 
Therapeutic Drug Monitoring (TDM) is defined as the use of drug concentrations to optimise drug 
therapy for individual patient. The idea that intensity and duration of pharmacological response is 
dependent on serum concentration was first reported by Marshalland, then tested for the screening 
of antimalarials during World War II. Since 1960s extensive research was directed in developing 
specific and sensitive analytical methods for serum drug concentration measurements.  
 
Currently, drug concentration assays most widely available in hospital laboratory are for: antiepilep-
tics (Carbamazepine, Ethosuximide, Phenobarbital, Phenytoin and Valproic acid), cardiac drugs 
(Digoxin, Procainamide and Quinidine), antibiotics (Aminoglycosides and Vancomycin), Theophyl-
line, Cyclosporine and Lithium.  
As a general rule, the serum drug concentrations are affected by following factors: 
• Patient’s renal or hepatic function 
• Protein binding capacity (Albumin level) 
• Electrolytes (particularly K+ and Mg+2) 
• Sample timing with respect to dose (loading as well as maintenance) and route  
• Drug-Drug Interaction 
• Drug-Food interaction  
 
Treatment and prophylaxis of Erythema nodosum leprosum is another FDA approved indication for  
  Thalidomide 
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CELECOXIB -- WARFARIN 
Adverse Effect: Concurrent use of Celecoxib and Warfarin may result in an increased risk of bleeding. 
Clinical Management 
Use caution when these agents are coadministered and monitor prothrombin time during concomi-
tant treatment, especially in the first few days after initiating or changing celecoxib therapy. This 
combination does not appear to be potentially harmful in long term concomitant therapy.  
 
Onset: delayed  
Severity: major  
Documentation: good  
Probable Mechanism: competition for metabolism through cytochrome P450 2C9 enzymes 
Drug Interaction Update 
 
Answer  
